We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

49 hedge funds and large institutions have $6.65M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

4% more funds holding

Funds holding: 47 → 49 (+2)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

29% less capital invested

Capital invested by funds: $9.3M → $6.65M (-$2.65M)

81% less call options, than puts

Call options by funds: $44K | Put options by funds: $233K

Holders
49
Holders Change
+2
Holders Change %
+4.26%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
10
Closed
3
Calls
$44K
Puts
$233K
Net Calls
-$189K
Net Calls Change
+$506K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$3.05M
2
B
Bailard
California
+$222K
3
VKH
Virtu KCG Holdings
New York
+$104K
4
TSS
Two Sigma Securities
New York
+$66.6K
5
Renaissance Technologies
Renaissance Technologies
New York
+$43.3K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$369K
2
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$75K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$58.1K
4
GBA
Garrison Bradford & Associates
New York
-$25.4K
5
Citadel Advisors
Citadel Advisors
Florida
-$11.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
26
Two Sigma Securities
New York
$38K +$66.6K +63 New
FNBT
27
FineMark National Bank & Trust
Florida
$34K – – –
PNC Financial Services Group
28
PNC Financial Services Group
Pennsylvania
$30K -$75K -71 -59%
WMC
29
Westwood Management Corporation
Illinois
$30K – – –
Deutsche Bank
30
Deutsche Bank
Germany
$29K – – –
UBS Group
31
UBS Group
Switzerland
$25K – – –
CG
32
Cutler Group
California
$23K – – –
Squarepoint
33
Squarepoint
New York
$23K +$40.1K +38 New
Citadel Advisors
34
Citadel Advisors
Florida
$17K -$11.6K -11 -28%
Janney Montgomery Scott
35
Janney Montgomery Scott
Pennsylvania
$17K -$1.06K -1 -3%
Creative Planning
36
Creative Planning
Kansas
$17K – – –
AIM
37
Acrospire Investment Management
Illinois
$17K +$12.7K +12 +75%
State Street
38
State Street
Massachusetts
$16K – – –
WSFS
39
Wilmington Savings Fund Society
Delaware
$15K – – –
BA
40
BlackRock Advisors
Delaware
$14K – – –
First Manhattan
41
First Manhattan
New York
$10K – – –
Morgan Stanley
42
Morgan Stanley
New York
$7K -$2.11K -2 -14%
BIM
43
BlackRock Investment Management
Delaware
$7K – – –
CLOS
44
Compagnie Lombard Odier SCmA
Switzerland
$6K – – –
WA
45
WFG Advisors
Texas
$6K – – –
TRCT
46
Tower Research Capital (TRC)
New York
$5K +$9.51K +9 New
Simplex Trading
47
Simplex Trading
Illinois
$2K – – –
Bank of America
48
Bank of America
North Carolina
$1K – – –
IA
49
IFP Advisors
Florida
$1K – – –
Bank of Montreal
50
Bank of Montreal
Ontario, Canada
– -$7K -6 Closed
1
2
3

NBSE Hedge Fund Activity: Q4 2016 in Review

49 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2016, worth a combined $6.65M — down 29% from $9.3M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NBSE positions and 3 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $3.05M. The largest seller was Vanguard Group, cutting an estimated $369K.

  • 49 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2016, up from 47 in Q3 2016.
  • Funds reported $6.65M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2016, down 29% quarter-over-quarter.
  • 5 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2016 and 3 closed out, a net change of +2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2016 was Sabby Management, an estimated $3.05M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2016 was Vanguard Group, an estimated $369K sold.

Based on aggregated 13F filings for Q4 2016.